Point72 Hong Kong LTD Tg Therapeutics, Inc. Transaction History

Point72 Hong Kong LTD

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	BUY	$4.57 - $8.4 $77,434 - $142,329	16,944 Added 3667.53%	17,406 $103,000
Q2 2022 Aug 15, 2022	BUY	$3.74 - $10.66 $1,727 - $4,924	462 New	462 $2,000
Q1 2022 May 16, 2022	SELL	$7.81 - $20.45 $40,502 - $106,053	-5,186 Closed	0 $0
Q4 2021 Feb 14, 2022	BUY	$15.2 - $35.51 $78,827 - $184,154	5,186 New	5,186 $99,000
Q3 2021 Nov 15, 2021	SELL	$21.78 - $40.45 $31,711 - $58,895	-1,456 Closed	0 $0
Q2 2021 Aug 16, 2021	BUY	$32.5 - $48.96 $47,320 - $71,285	1,456 New	1,456 $56,000
Q2 2020 Aug 14, 2020	SELL	$8.9 - $21.84 $2,296 - $5,634	-258 Closed	0 $0
Q1 2020 May 15, 2020	SELL	$7.14 - $15.99 $11,216 - $25,120	-1,571 Reduced 85.89%	258 $3,000
Q4 2019 Feb 14, 2020	BUY	$5.1 - $11.2 $9,327 - $20,484	1,829 New	1,829 $20,000
Q4 2018 Feb 14, 2019	SELL	$3.44 - $5.76 $12,511 - $20,949	-3,637 Closed	0 $0
Q3 2018 Nov 14, 2018	BUY	$5.15 - $14.0 $18,730 - $50,918	3,637 New	3,637 $20,000

338

88.3M

2.35M

1.7M

Ticker TGTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 145,274,000
Market Cap $4.29B
Description
TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its therapeutic product candidates include Ublituximab, an investigational glycoengineered monoclonal antibody for the treatment of B-cell non-hod...

Get notified when there are updates to the investment portfolio of Point72 Hong Kong LTD, based on Form 13F filings with the SEC.

Stay updated on Point72 Hong Kong LTD with notifications on news.